Expression of Prostate Specific Molecules in Bacille Calmette‐Guerin: An Immunotherapeutic Approach to Prostate Cancer

The open prostate cancer journal Pub Date : 2001-04-01 DOI:10.1046/J.1525-1411.2001.32002.X

C. Zeoli, M. Maitland, Herbert Rose, B. Bloom, A. Mittelman, J. Geliebter

{"title":"Expression of Prostate Specific Molecules in Bacille Calmette‐Guerin: An Immunotherapeutic Approach to Prostate Cancer","authors":"C. Zeoli, M. Maitland, Herbert Rose, B. Bloom, A. Mittelman, J. Geliebter","doi":"10.1046/J.1525-1411.2001.32002.X","DOIUrl":null,"url":null,"abstract":"Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. \n \n \n \nResults: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. \n \n \n \nDiscussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. \n \n \n \nConclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"24 1","pages":"92-97"},"PeriodicalIF":0.0000,"publicationDate":"2001-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The open prostate cancer journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/J.1525-1411.2001.32002.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

前列腺特异性分子在卡介苗中的表达:前列腺癌的免疫治疗方法

目的:目的是开发一种用于治疗转移性前列腺癌的免疫治疗疫苗。结果:卡介苗(Bacille Calmette Guerin, BCG)表达前列腺特异性抗原(PSA)或前列腺特异性膜抗原(PSMA)。Western blotting技术表明重组卡介苗(rBCG)在rBCG细菌裂解物中每1 μg微克蛋白表达约25 ng PSA或112 pg PSMA。讨论:结核疫苗卡介苗是一种有效的免疫佐剂，可刺激体液免疫系统和细胞免疫系统。前列腺癌患者可以产生细胞毒性淋巴细胞，对抗来自正常、自我分子(如PSA和PSMA)的特定肽。因此，表达前列腺特异性蛋白的rBCG疫苗可能会刺激免疫反应来识别和摧毁前列腺癌细胞。结论:卡介苗可表达前列腺特异性分子，可作为前列腺癌免疫治疗疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

The open prostate cancer journal

自引率

0.00%

发文量